335 related articles for article (PubMed ID: 27140409)
1. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
3. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
Larenas-Linnemann D
Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
[TBL] [Abstract][Full Text] [Related]
5. Allergen immunotherapy for birch-apple syndrome: what do we know?
Incorvaia C; Ridolo E; Mauro M; Russello M; Pastorello E
Immunotherapy; 2017 Nov; 9(15):1271-1278. PubMed ID: 29130794
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
[TBL] [Abstract][Full Text] [Related]
7. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological correlates of pre-co-seasonal sublingual immunotherapy with birch monomeric allergoid in patients with allergic rhinoconjunctivitis.
Burastero SE; Mistrello G; Paolucci C; Breda D; Roncarolo D; Zanotta S; Falagiani P
Int J Immunopathol Pharmacol; 2009; 22(2):343-52. PubMed ID: 19505388
[TBL] [Abstract][Full Text] [Related]
9. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Buczyłko K; van der Werf JF; Boot D; van Ree R
Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen.
Grönlund H; Gafvelin G
Hum Vaccin; 2010 Dec; 6(12):970-7. PubMed ID: 21157177
[TBL] [Abstract][Full Text] [Related]
11. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
12. Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety.
Creticos PS; Pfaar O
Immunotherapy; 2018 Jun; 10(7):605-616. PubMed ID: 29634392
[TBL] [Abstract][Full Text] [Related]
13. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
[TBL] [Abstract][Full Text] [Related]
14. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly.
Campana R; Vrtala S; Maderegger B; Jertschin P; Stegfellner G; Swoboda I; Focke-Tejkl M; Blatt K; Gieras A; Zafred D; Neubauer A; Valent P; Keller W; Spitzauer S; Valenta R
J Allergy Clin Immunol; 2010 Nov; 126(5):1024-31, 1031.e1-8. PubMed ID: 20638112
[TBL] [Abstract][Full Text] [Related]
15. Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1.
Akinfenwa O; Huang HJ; Linhart B; Focke-Tejkl M; Vrtala S; Poroshina A; Nikonova A; Khaitov M; Campion NJ; Eckl-Dorna J; Niederberger-Leppin V; Kratzer B; Tauber PA; Pickl WF; Kundi M; Campana R; Valenta R
Front Immunol; 2021; 12():744544. PubMed ID: 34795666
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.
Nony E; Bouley J; Le Mignon M; Lemoine P; Jain K; Horiot S; Mascarell L; Pallardy M; Vincentelli R; Leone P; Roussel A; Batard T; Abiteboul K; Robin B; de Beaumont O; Arvidsson M; Rak S; Moingeon P
Allergy; 2015 Jul; 70(7):795-804. PubMed ID: 25846209
[TBL] [Abstract][Full Text] [Related]
17. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4.
Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T
Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
Purohit A; Niederberger V; Kronqvist M; Horak F; Grönneberg R; Suck R; Weber B; Fiebig H; van Hage M; Pauli G; Valenta R; Cromwell O
Clin Exp Allergy; 2008 Sep; 38(9):1514-25. PubMed ID: 18564326
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
20. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
